Major generic companies are challenging the unlisted patent of 'Trajenta (linagliptin)', a DPP-4 inhibitor-based diabetes treatment. For 6 months since last September, 10 pharmaceutical companies have successively filed trials on 7 patents.

It is believed that the companies are aiming for the release of Trajenta generics and Trajenta+Forxiga (dapagliflozin) combination products, as the product patent expires next year.

According to the pharmaceutical industry, Sinil Pharmaceutical, Hutecs Korea Pharmaceutical and Hanlim Pharm recently simultaneously filed a defensive confirmation trial for the scope of rights and invalidation trial on three unlisted patents, on the 24th. The patents are